GLP-1 and Addiction: Can Ozempic, Wegovy, or Mounjaro Help Fight Alcoholism and Drug Use?

Quick Answer:

Yes, emerging research shows GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound may significantly reduce cravings and use across multiple addictions, including alcohol, opioids, nicotine, cocaine, and cannabis.

What the research shows:

50% reduction in alcohol intoxication events
40% reduction in opioid overdose risk
42-68% lower risk of opioid overdose compared to other diabetes medications
Reduced cigarette consumption and nicotine cravings
18-25% lower risk of developing new substance use disorders

While GLP-1 medications aren’t approved for addiction treatment yet, the evidence is compelling enough that clinical trials are underway to study them specifically for substance use disorders.

If you or someone you know is taking a GLP-1 medication for weight loss or diabetes, you may have noticed something unexpected: suddenly, that glass of wine doesn’t seem as appealing. The cigarettes you’ve smoked for years feel less satisfying. The urge to drink feels… quieter.

You’re not imagining it. And you’re not alone.

In This Guide

The Accidental Discovery: How We Learned GLP-1s Affect Addiction
The Science: Why GLP-1s May Work for Addiction
GLP-1s and Alcohol Use Disorder
GLP-1s and Opioid Addiction
GLP-1s and Nicotine/Smoking
GLP-1s and Other Substances (Cocaine, Cannabis)
The Mechanisms: How Do GLP-1s Affect Addiction?
Current Clinical Trials and Research
Important Limitations and Cautions
The Future of GLP-1s in Addiction Treatment
Frequently Asked Questions
Key Takeaways
Your Next Steps

The Accidental Discovery: How We Learned GLP-1s Affect Addiction

The connection between GLP-1 medications and addiction wasn’t discovered in a lab. It was discovered by patients.

As millions of people started taking Ozempic, Wegovy, Mounjaro, and Zepbound for weight loss and diabetes, doctors began hearing unexpected reports. Patients who had struggled with alcohol for years suddenly found themselves having just one drink instead of five. Lifelong smokers reported that cigarettes no longer gave them the same satisfaction. People with opioid use disorder found their cravings mysteriously diminished.

At first, these reports were anecdotal. Easy to dismiss as coincidence or placebo effect. But as the stories accumulated and researchers began digging into the data, a pattern emerged that was impossible to ignore.

The Landmark Study

In March 2026, researchers at Washington University School of Medicine published what may be the most comprehensive study yet on GLP-1s and addiction. They analyzed data from over 600,000 U.S. veterans with type 2 diabetes and found something remarkable:

Compared to patients taking other diabetes medications, those on GLP-1s had:

50% reduction in drug-related deaths
40% reduction in overdoses
26% fewer drug-related hospitalizations
25% reduction in suicide attempts
30% reduction in emergency department visits for substance use

These weren’t small differences. These were the kinds of reductions that, if confirmed, could save thousands of lives.

The Science: Why GLP-1s May Work for Addiction

To understand why weight loss drugs might help with addiction, you need to understand how GLP-1 works in the brain.

It’s Not Just About the Gut

Yes, GLP-1 medications slow stomach emptying and make you feel full. That’s how they help with weight loss. But GLP-1 receptors aren’t just in your stomach. They’re throughout your brain, particularly in areas involved in reward, motivation, and craving.

The same brain regions that light up when you eat delicious food also light up when you drink alcohol, smoke a cigarette, or use drugs. These are the dopamine reward pathways, and they’re fundamental to addiction.

The Overlapping Pathways

Here’s where it gets interesting. Research shows that obesity and addiction share remarkably similar brain mechanisms. Both involve:

Dysregulated dopamine signaling
Impaired impulse control
Heightened reward sensitivity
Difficulty feeling satisfied

When GLP-1 medications activate receptors in the brain’s reward centers, they appear to dampen these signals. Not eliminate them, but turn down the volume. The result? Substances that once felt intensely rewarding feel less compelling.

The “Satiety Signal” Theory

One hypothesis is that GLP-1 medications enhance satiety signaling in the brain. Just as they make you feel full after eating less food, they may create a sense of “enough” with substances like alcohol or drugs. You reach satisfaction sooner and don’t feel compelled to keep going.

GLP-1s and Alcohol Use Disorder

The evidence for GLP-1s and alcohol use disorder is perhaps the strongest and most studied.

The Clinical Trial Data

A randomized, placebo-controlled trial published in JAMA Psychiatry in 2025 found that low-dose semaglutide (the active ingredient in Ozempic and Wegovy):

Reduced drinks per drinking day
Decreased heavy drinking days
Lowered alcohol cravings (39% reduction)
Reduced laboratory alcohol self-administration

Importantly, these effects were seen even at doses lower than typically used for weight loss, suggesting the anti-alcohol effects may be independent of weight reduction.

Real-World Evidence

Beyond clinical trials, observational studies paint an even more dramatic picture:

50% reduction in alcohol intoxication events requiring hospitalization
18% lower risk of developing alcohol use disorder among people taking GLP-1s
Reduced alcohol consumption even in people who don’t have diagnosed alcohol use disorder

How It Feels

Patients describe the change in their relationship with alcohol as subtle but profound. It’s not that alcohol becomes disgusting or that cravings disappear entirely. Instead, many report:

Feeling satisfied after one or two drinks instead of wanting more
Less desire to drink in the first place
Alcohol tasting less appealing
Not thinking about drinking as often
Finding it easier to stop once they start

One patient described it as “the volume being turned down on the obsession.”

The Gut Connection

There’s also a physical component. GLP-1 medications slow gastric emptying, which means alcohol stays in your stomach longer and gets absorbed more slowly. This leads to lower blood alcohol levels in the first 20-30 minutes after drinking, making people feel less intoxicated initially. This may reduce the rewarding “rush” that keeps people drinking.

GLP-1s and Opioid Addiction

The potential for GLP-1s to help with opioid use disorder may be even more life-saving than their effects on alcohol.

The Overdose Data

Multiple studies have found dramatic reductions in opioid overdose risk among people taking GLP-1 medications:

42-68% lower risk of opioid overdose compared to other diabetes medications
40% reduction in overdose among people with pre-existing opioid use disorder
40% reduction in opioid cravings in a small 3-week study

Given that over 100,000 Americans die from opioid overdoses each year, even modest reductions in overdose risk could save thousands of lives.

Animal Research

Preclinical studies in rodents have shown that GLP-1 receptor agonists:

Reduce self-administration of heroin, fentanyl, and oxycodone
Decrease drug-seeking behavior (a model of relapse)
Reduce the rewarding effects of opioids
Block reinstatement of opioid seeking after abstinence

The Clinical Promise

Here’s what makes this so significant: current medications for opioid use disorder (methadone, buprenorphine, naltrexone) work well for many people, but not everyone responds to them or can tolerate them. GLP-1 medications could offer an additional tool, particularly for people with co-occurring obesity or diabetes.

A small study found that people with opioid use disorder who took GLP-1 medications had a 40% reduction in cravings within just three weeks. While small and preliminary, these findings are encouraging enough that larger trials are underway.

GLP-1s and Nicotine/Smoking

Nicotine addiction is notoriously difficult to treat, and most quit attempts end in relapse. Could GLP-1 medications help?

The Smoking Data

Research suggests GLP-1s may help with smoking cessation in several ways:

Reduced cigarettes per day in smokers taking GLP-1s
Lower nicotine cravings
20% reduced risk of developing nicotine use disorder
Prevention of post-quit weight gain (a major reason people relapse)

The Weight Gain Factor

One of the biggest barriers to quitting smoking is weight gain. On average, people gain 10-15 pounds after quitting, which leads many to start smoking again. GLP-1 medications could be a game-changer here by addressing both the nicotine cravings and the weight gain simultaneously.

Clinical Trial Results

A 2021 pilot study found that adding a GLP-1 drug to nicotine patch treatment nearly doubled the quit rate in prediabetic or overweight smokers. While small, this study has led to larger trials currently underway.

Animal Studies

In rodent models, GLP-1 receptor agonists:

Reduce nicotine self-administration
Decrease reinstatement of nicotine seeking
Reduce the rewarding effects of nicotine
Alleviate withdrawal symptoms like anxiety and cognitive deficits

GLP-1s and Other Substances (Cocaine, Cannabis)

While less studied than alcohol, opioids, and nicotine, early research suggests GLP-1s may help with other substance use disorders too.

Cocaine

Animal research shows promising results:

GLP-1 receptor activation reduces cocaine self-administration
Reduces cocaine-seeking behavior during abstinence
Decreases the reinforcing effects of cocaine
Blocks reinstatement of cocaine seeking

The Washington University study found a 20% reduced risk of developing cocaine use disorder among people taking GLP-1s.

Cannabis

The same large-scale study found a 14% reduced risk of developing cannabis use disorder. While this is less dramatic than the effects seen with other substances, it still suggests GLP-1s may have broad anti-addiction properties.

The Common Mechanism

What’s remarkable about these findings is that GLP-1s seem to work across multiple different substances, each with different brain mechanisms. This suggests they may be targeting something fundamental to addiction itself, not just specific drug pathways.

The Mechanisms: How Do GLP-1s Affect Addiction?

Scientists are still working to fully understand how GLP-1 medications reduce substance use, but several mechanisms are likely involved:

1. Dopamine Reward Signaling

GLP-1 receptors are found in brain regions rich in dopamine, including the ventral tegmental area (VTA) and nucleus accumbens. Activating these receptors appears to modulate dopamine release, potentially reducing the “high” from addictive substances.

2. The Satiety Signal

GLP-1 normally signals “you’ve had enough” for food. This same signal may extend to other rewarding substances, creating a sense of satisfaction sooner and reducing the compulsion to keep using.

3. Stress and Emotional Regulation

GLP-1 receptors in areas like the amygdala and hippocampus may help regulate stress and negative emotions, both of which are major triggers for substance use.

4. Craving Reduction

Brain imaging studies show that GLP-1 medications reduce neural responses to reward-related cues. This may mean that seeing a beer commercial or smelling cigarette smoke triggers less intense cravings.

5. Withdrawal Symptom Relief

Animal studies suggest GLP-1 receptor agonists may reduce anxiety, depression, and cognitive deficits during withdrawal, making it easier to stay abstinent.

Current Clinical Trials and Research

The evidence so far is compelling enough that formal clinical trials are underway:

Ongoing Studies

NEST-1 Trial: Testing semaglutide for alcohol use disorder
IGNITE Trial: Examining GLP-1s for smoking cessation
OUD Trials: Multiple studies testing GLP-1s for opioid use disorder

These randomized, controlled trials will provide the gold-standard evidence needed to determine if GLP-1s should be officially approved for treating addiction.

What We’re Waiting to Learn

Optimal dosing for addiction treatment (may differ from weight loss doses)
Which specific GLP-1 medication works best for which addiction
Long-term efficacy and safety
Whether effects persist after stopping the medication
Cost-effectiveness compared to existing addiction treatments

Important Limitations and Cautions

Before you get too excited, here are critical points to understand:

1. GLP-1s Are Not a Cure for Addiction

Addiction is complex and typically requires comprehensive treatment including therapy, support groups, lifestyle changes, and sometimes medication. GLP-1s may be a powerful tool, but they’re not a magic bullet.

2. Most Evidence Is Observational

The large studies showing dramatic benefits are observational, meaning they can show associations but not definitive cause-and-effect. Randomized controlled trials are still ongoing.

3. We Don’t Know Long-Term Effects

What happens when someone stops taking GLP-1s? Do cravings come back? We don’t have good long-term data yet.

4. They’re Not FDA-Approved for Addiction

Currently, GLP-1 medications are only approved for diabetes and weight loss. Prescribing them specifically for addiction would be off-label.

5. Cost and Access Issues

GLP-1 medications can be expensive ($900-1,500/month for name brand options without insurance). Many addiction treatment programs and insurance plans don’t cover them for substance use disorders. Compounded options offer the same active ingredients as the name brands at a fraction of the price. Keep in mind they are not FDA approved however they are produced in regulated pharmacies.

Skinny Rx is one of the top rated online GLP-1 providers offering budget friendly compounded options:

Check Out Skinny RX to see if you Qualify

6. Side Effects Still Apply

All the usual GLP-1 side effects (nausea, vomiting, diarrhea, etc.) still occur. Some people can’t tolerate these medications.

7. Not a Substitute for Standard Addiction Treatment

If you have opioid use disorder, you shouldn’t skip methadone or buprenorphine in favor of GLP-1s. These proven medications save lives.

The Future of GLP-1s in Addiction Treatment

If ongoing clinical trials confirm the observational findings, GLP-1 medications could revolutionize addiction treatment.

Why This Matters

Current addiction treatments work, but they’re far from perfect:

Only 10-20% of people with substance use disorders receive treatment
Relapse rates are high (40-60% within the first year)
Existing medications don’t work for everyone
There’s significant stigma around addiction treatment

GLP-1 medications offer something unique: they’re already widely prescribed, socially acceptable, and may work across multiple addictions simultaneously. Someone could start taking a GLP-1 for weight loss and find it helps with their drinking problem too, without the stigma of going to a specialized addiction clinic.

The Paradigm Shift

If GLP-1s work as the early evidence suggests, it would represent a fundamental shift in how we understand and treat addiction. Instead of treating each substance separately, we might be able to target the underlying brain mechanisms that make people vulnerable to addiction in the first place.

What Needs to Happen Next

For GLP-1s to become standard addiction treatment, we need:

Completed randomized controlled trials showing efficacy and safety
FDA approval for substance use disorder indications
Insurance coverage for addiction treatment
Training for addiction specialists on how to use these medications
Long-term safety data on using GLP-1s in people with substance use disorders

Should You Try GLP-1s for Addiction?

This is a question for your doctor, but here are some considerations:

You Might Be a Good Candidate If:

You have co-occurring obesity or type 2 diabetes (already approved indications)
You’ve tried standard addiction treatments without success
You have insurance coverage or can afford the cost
You’re willing to participate in a clinical trial
You want to address both weight and substance use simultaneously

You Should Stick with Proven Treatments If:

You’re currently stable on methadone or buprenorphine for opioid use disorder (don’t switch)
You can’t tolerate GLP-1 side effects (nausea, vomiting)
You don’t have insurance and can’t afford $900-1,500/month for name brand options
You aren’t willing to pay $200-$300/month out of pocket for compounded options
You have contraindications to GLP-1s (history of pancreatitis, thyroid cancer, etc.)

Talk to Your Doctor If:

You’re already on a GLP-1 and notice changes in your substance use
You’re interested in trying GLP-1s specifically for addiction
You want to know if you qualify for a clinical trial
You have questions about whether this could help your specific situation

The Bottom Line on GLP-1s and Addiction

The evidence that GLP-1 medications can help with addiction is mounting and impressive. We’re seeing 40-50% reductions in overdoses, intoxication events, and substance-related deaths. We’re seeing people spontaneously cut back on drinking, smoking, and drug use.

But we’re still in early days. Most evidence comes from observational studies and animal research. We need the ongoing clinical trials to confirm these effects and establish proper dosing, safety, and efficacy.

What we know for sure:

GLP-1s affect brain reward pathways involved in addiction
Observational data shows substantial reductions in substance use and related harms
The effects appear to work across multiple different substances
Patients are reporting real changes in their cravings and use

What we don’t know yet:

Whether randomized trials will confirm the observational findings
What the optimal dosing should be for addiction treatment
How long people need to stay on them
What happens when they stop
Which specific populations benefit most

If you’re taking a GLP-1 medication and notice changes in your substance use, you’re experiencing what may be one of the most important unexpected benefits of these medications. If you’re struggling with addiction and wondering if GLP-1s could help, talk to your doctor about whether they might be appropriate for you, especially if you also have obesity or diabetes.

The future of addiction treatment may not look like we expected. It may come in a weekly injection originally designed for diabetes, discovered by accident, and proven through the lived experiences of millions of patients.

Frequently Asked Questions

Can GLP-1 medications cure addiction?

No. GLP-1 medications are not a cure for addiction. They appear to reduce cravings and substance use, but addiction is complex and typically requires comprehensive treatment including therapy, support groups, and lifestyle changes. GLP-1s may be a powerful tool as part of a broader treatment plan, but they’re not a standalone cure.

Do I need to have diabetes or obesity to get GLP-1s for addiction?

Currently, yes. GLP-1 medications are only FDA-approved for type 2 diabetes and obesity/weight management. Prescribing them specifically for substance use disorders would be off-label. However, if you have co-occurring obesity or diabetes, your doctor may prescribe them for those conditions, and you may experience addiction-related benefits as well.

Which GLP-1 medication works best for addiction?

We don’t know yet. Most research has focused on semaglutide (Ozempic, Wegovy), but studies suggest the effects may be a class-wide phenomenon affecting all GLP-1 receptor agonists. Ongoing clinical trials will help determine if specific medications work better for certain addictions.

Will my cravings come back if I stop taking GLP-1s?

We don’t have good long-term data on this yet. Some patients report that cravings return after stopping GLP-1s, while others find that the break in their addiction patterns helps them maintain abstinence. More research is needed to understand the long-term effects.

Can I take GLP-1s along with medications like methadone or buprenorphine?

Potentially, yes, but you should only do this under medical supervision. If you’re currently stable on medication-assisted treatment for opioid use disorder, don’t stop or switch without consulting your doctor. Early research suggests GLP-1s may complement existing addiction treatments, but we need more data on safety and interactions.

How long does it take for GLP-1s to reduce substance cravings?

This varies by person and substance. Some patients report noticing reduced cravings within the first few weeks, while others take longer. In clinical trials, effects on alcohol use were seen within 2-4 weeks of starting treatment. Be patient and work with your healthcare provider to monitor your response.

Are GLP-1 medications covered by insurance for addiction treatment?

Generally, no. Insurance typically only covers GLP-1 medications for their approved indications (diabetes and obesity). However, if you have co-occurring obesity or diabetes, your insurance may cover them for those conditions. Some clinical trials are also recruiting participants, which would provide the medication at no cost.

Key Takeaways

GLP-1s show promise across all major addictions: Research suggests these medications may help with alcohol, opioids, nicotine, cocaine, and cannabis addiction, not just one substance
The effects are substantial: Studies show 40-50% reductions in overdoses, intoxication events, and substance-related deaths
It’s not just about weight loss: The anti-addiction effects appear even in people who aren’t losing significant weight
The brain’s reward system is involved: GLP-1 receptors in the brain may dampen the pleasure response to addictive substances
Clinical trials are ongoing: Formal studies are underway to determine if GLP-1s should be prescribed specifically for addiction treatment
This isn’t a cure: GLP-1 medications show promise as part of comprehensive addiction treatment, not as a standalone solution
It’s still early: Most evidence comes from observational studies and animal research; large randomized trials are still needed

Your Next Steps

Considering starting a GLP-1 medication? Read our comprehensive reviews of the top providers:

Want to understand how GLP-1s work? Learn about the science behind these medications:

Concerned about other unexpected effects? Read our guides on other surprising GLP-1 impacts:

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Substance use disorders are serious medical conditions that require professional treatment. GLP-1 medications are not currently FDA-approved for treating addiction, and most evidence comes from observational studies and early clinical trials. Never stop taking prescribed addiction medications (like methadone, buprenorphine, or naltrexone) without consulting your healthcare provider. Always discuss any changes to your treatment plan with a qualified medical professional who knows your complete medical history.

If you or someone you know is struggling with substance use, contact SAMHSA’s National Helpline at 1-800-662-4357 (free, confidential, 24/7) for treatment referrals and information.

Sources

Jerlhag E, et al. GLP-1 receptor agonists and alcohol use disorder: Preclinical and clinical evidence. Neuropharmacology. 2025;181:108892.
Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder. JAMA Psychiatry. 2025;82(4):341-349.
Leggio L, et al. GLP-1s show promise in treating alcohol and drug addiction. Endocrine Society Press Release. October 2025.
Wang W, et al. Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. JAMA Network Open. 2024;7(9):e2433991.
Xu R, et al. Association of Glucagon-like Peptide-1 Receptor Agonists With Substance Use Disorders in Patients With Type 2 Diabetes. Washington University School of Medicine. 2026;285(9):821-829.
Herman RJ, et al. Targeting GLP-1 receptors to reduce nicotine use disorder. Physiology & Behavior. 2024;281:114565.
DiFeliceantonio AG, et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology. 2025;50(3):558-567.
Hernandez NS, et al. Central GLP-1 Receptors: Novel Molecular Targets for Cocaine Use Disorder. Physiology & Behavior. 2019;206:93-105.
Klausen MK, et al. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology. 2022;179(4):625-641.
Lembke A. Five things to know about GLP-1s and addiction. Stanford Medicine Insights. July 2025.
NIAAA. Semaglutide Shows Promise as a Potential Alcohol Use Disorder Medication. NIH Spectrum. Winter 2024.
Xavier S, et al. GLP-1 Receptor Agonists May Support Nicotine Cessation. American Psychiatric Association Press Release. May 2025.

Affiliate Disclaimer

This article contains affiliate links to compounded GLP-1 providers I’ve personally reviewed and recommend. If you sign up through my links, I may earn a commission at no additional cost to you. This helps me continue providing free, evidence-based content about GLP-1 medications. I only recommend providers I’ve thoroughly vetted and would use myself. My reviews and recommendations remain independent and unbiased regardless of affiliate relationships.

Important Note: This article discusses off-label uses of GLP-1 medications. I do not receive any compensation from pharmaceutical companies or addiction treatment centers for this content. All research cited is from peer-reviewed scientific journals and reputable medical institutions.

Last Updated: April 2026